Taysha Gene Therapies, Inc. (TSHA)
|52 Week Range||0.6806-7.077|
|1y Target Est||-|
|DCF Unlevered||TSHA DCF ->|
|DCF Levered||TSHA LDCF ->|
|Debt / Equity||901.87%||Strong Buy|
Upgrades & Downgrades
Latest TSHA news
Taysha: The FDA Just Stuck A Major Blow To Their Plans
6 February 2023
Taysha has a good chance of scoring with the GAN indication. Astellas may license this program if that happens.
Best Penny Stocks To Buy Now? 5 Biotech Stocks To Watch This Week
21 November 2022
Biotech penny stocks to watch this week. Are they a buy now?
Taysha Gene Therapies: Astellas Throws Lifeline For First Dibs On Rett And GAN Programs
17 November 2022
Shares have fallen by 85% since Sept 2020 IPO as cash resources dwindled to $34M as of last month. Company was forced to cut 35% of workforce, stop construction of its cGMP manufacturing facility and ...
Taysha Gene Therapies, Inc. (TSHA) Q3 2022 Results - Earnings Call Transcript
13 November 2022
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q3 2022 Results Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Kimberly Lee - Chief Corporate Affairs Officer RA Session - Preside...
5 Penny Stocks To Buy According To Analysts, Targets Up To 995%
8 November 2022
Analysts say these are penny stocks to buy. Do you agree?
Taysha Gene Therapies to Release Third Quarter 2022 Financial Results and Host Conference Call and W...
2 November 2022
DALLAS, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene the...
Buying Penny Stocks? 3 Technical Indicators to Use
26 October 2022
Use these technical indicators for trading penny stocks right now The post Buying Penny Stocks? 3 Technical Indicators to Use appeared first on Penny Stocks to Buy, Picks, News and Information | Penn...
What Is Going on With Taysha Gene (TSHA) Stock Today?
25 October 2022
Taysha Gene Therapies (NASDAQ: TSHA ) jumped 50% overnight after Japan's Astellas Pharma (OTCMKTS: ALPMY ) bought 15% of the company and exclusive marketing rights to its genetic therapies. Taysha is ...
Taysha Gene Therapies to Host Conference Call to Discuss Astellas Pharma's Strategic Investment to S...
24 October 2022
Conference call and webcast on Tuesday, October 25 at 8:00 AM ET Conference call and webcast on Tuesday, October 25 at 8:00 AM ET
Taysha Gene Therapies, Inc. (TSHA) CEO RA Session on Q2 2022 Results - Earnings Call Transcript
13 August 2022
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q2 2022 Results Conference Call August 11, 2022 8:00 AM ET Company Participants Dr. Kimberly Lee - Chief Corporate Affairs Officer RA Session - President, Fo...
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >